Asia-Pacific Lung Cancer Surgery Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Asia-Pacific Lung Cancer Surgery Market Size

• The Asia-Pacific lung cancer surgery market size was valued at USD 1.08 billion in 2025 and is expected to reach USD 1.72 billion by 2033, at a CAGR of 6.0% during the forecast period
• The market growth is primarily driven by the rising incidence of lung cancer across countries such as China, India, and Japan, along with increasing adoption of advanced surgical techniques including minimally invasive and robotic-assisted thoracic surgeries, leading to improved patient outcomes and shorter recovery times
• Furthermore, expanding healthcare infrastructure, growing awareness regarding early cancer diagnosis, and increasing government initiatives to strengthen oncology care are establishing surgical intervention as a key treatment approach. These combined factors are accelerating the demand for lung cancer surgeries, thereby significantly boosting the market growth

Asia-Pacific Lung Cancer Surgery Market Analysis

• Lung cancer surgery, involving procedures supported by surgical instruments, monitoring and visualizing systems, endosurgical equipment, robotic-assisted thoracic surgery systems and others, plays a critical role in the treatment of early- and mid-stage lung cancer, and is increasingly becoming a cornerstone of oncology care across hospitals and specialized cancer centers in the Asia-Pacific region
• The escalating demand for lung cancer surgery is primarily fueled by the rising prevalence of lung cancer due to smoking, air pollution, and occupational hazards, along with increasing awareness regarding early diagnosis and the growing adoption of advanced surgical technologies, particularly minimally invasive and robotic-assisted procedures
• China dominated the Asia-Pacific lung cancer surgery market with the largest revenue share of 32.6% in 2025, characterized by a high patient pool, improving healthcare infrastructure, and strong government initiatives to expand oncology treatment access, with significant growth observed in hospitals adopting advanced monitoring, visualization, and robotic surgical systems
• India is expected to be one of the fastest growing countries in the Asia-Pacific lung cancer surgery market during the forecast period due to increasing healthcare investments, rising cancer awareness programs, and improving access to specialized surgical care supported by expanding use of modern surgical equipment
• Minimally Invasive Surgery segment dominated the lung cancer surgery market with the highest market share of 58.4% in 2025, driven by its advantages such as reduced postoperative complications, shorter hospital stays

Report Scope and Asia-Pacific Lung Cancer Surgery Market Segmentation         

Asia-Pacific Lung Cancer Surgery Market Trends

 “Expansion of Minimally Invasive and Robotic-Assisted Surgical Approaches”

• A significant and accelerating trend in the Asia-Pacific lung cancer surgery market is the rapid shift toward minimally invasive surgery and robotic-assisted thoracic surgery systems, improving surgical precision, reducing complications, and enhancing patient recovery outcomes
• For instance, advanced thoracoscopic systems such as video-assisted thoracic surgery (VATS) are being widely adopted in leading hospitals across China and Japan, enabling surgeons to perform complex lung resections with smaller incisions and faster recovery times
• Integration of robotic-assisted platforms in thoracic procedures enables enhanced 3D visualization, tremor-free instrument control, and improved accuracy in tumor removal, with systems such as da Vinci surgical platforms increasingly used in complex lung cancer cases across tertiary care centers
• The increasing use of advanced monitoring and visualizing systems in operating rooms supports real-time imaging and better intraoperative decision-making, allowing surgeons to achieve higher precision in tumor localization and lymph node dissection during lung cancer surgeries
• This trend toward technologically advanced surgical systems is fundamentally reshaping surgical oncology practices, as hospitals increasingly invest in hybrid operating rooms combining imaging, robotics, and endosurgical equipment for improved clinical outcomes
• The demand for robotic-assisted thoracic surgery systems and minimally invasive solutions is growing rapidly across Asia-Pacific due to rising patient preference for less invasive procedures, reduced hospital stay, and faster post-operative recovery
• Continuous technological innovation in surgical instruments and imaging systems is enabling greater surgical precision and reducing intraoperative risks, thereby strengthening clinical confidence in advanced lung cancer procedures

Asia-Pacific Lung Cancer Surgery Market Dynamics

Driver

“Rising Lung Cancer Prevalence and Advancing Surgical Infrastructure”

• The increasing incidence of lung cancer across Asia-Pacific countries, combined with expanding healthcare infrastructure and oncology treatment capabilities, is a significant driver for the growing demand for lung cancer surgery procedures
• For instance, government-backed cancer control programs in countries such as China and India are enhancing early diagnosis rates and expanding access to surgical oncology services in both urban and semi-urban hospitals
• As awareness regarding early-stage cancer detection improves, patients are increasingly opting for surgical intervention as a primary treatment option, particularly when tumors are detected at resectable stages
• Furthermore, rising investments in advanced surgical equipment such as robotic-assisted thoracic surgery systems and high-precision imaging technologies are enabling hospitals to perform complex lung cancer surgeries with improved outcomes
• The growing availability of specialized thoracic surgeons and expansion of cancer care centers across the region are key factors accelerating surgical treatment adoption in both public and private healthcare sectors
• The increasing integration of advanced surgical instruments and minimally invasive techniques into routine oncology practice is further propelling the overall growth of the lung cancer surgery market in Asia-Pacific
• The rising adoption of multidisciplinary cancer care approaches combining surgery, chemotherapy, and radiotherapy is improving treatment outcomes and increasing surgical intervention rates
• Improved health insurance coverage and reimbursement policies in several Asia-Pacific countries are also supporting higher affordability and accessibility of lung cancer surgical procedures

Restraint/Challenge

“High Treatment Costs and Limited Access to Advanced Surgical Systems”

• Concerns regarding the high cost of advanced lung cancer surgical procedures, particularly those involving robotic-assisted systems and specialized endosurgical equipment, pose a significant challenge to broader market adoption in developing Asia-Pacific regions
• For instance, limited availability of robotic surgical platforms in rural hospitals and smaller healthcare centers restricts access to advanced lung cancer surgery for a large patient population
• The requirement for highly skilled surgeons and specialized training to operate advanced thoracic surgery systems further limits widespread adoption across underdeveloped healthcare facilities
• In addition, disparities in healthcare infrastructure between urban and rural regions create unequal access to minimally invasive and robotic-assisted surgical treatments for lung cancer patients
• While leading hospitals in countries such as Japan and South Korea are rapidly adopting advanced surgical technologies, many emerging economies still rely heavily on conventional thoracotomy procedures due to cost constraints
• Overcoming these challenges through increased healthcare funding, surgeon training programs, and wider deployment of cost-effective surgical systems will be essential for sustained market growth in the region
• Delayed diagnosis in rural and underserved populations further limits timely surgical intervention, reducing overall treatment effectiveness
• High maintenance and operational costs of robotic surgical systems also restrict their adoption in smaller healthcare facilities, slowing market penetration

Asia-Pacific Lung Cancer Surgery Market Scope

The market is segmented on the basis of product type, surgical procedure, patient type, end user, and distribution channel.

• By Product Type

On the basis of product type, the Asia-Pacific lung cancer surgery market is segmented into surgical instruments, monitoring & visualizing systems, endosurgical equipment, robotic-assisted thoracic surgery systems, and others. The surgical instruments segment dominated the market with the largest revenue share of 34.6% in 2025, driven by its essential role in all types of lung cancer surgical procedures, including thoracotomy and minimally invasive surgeries. These instruments form the backbone of operative workflows in hospitals and cancer centers across the region. Rising surgical volumes, particularly in China and India, continue to sustain strong demand for forceps, retractors, and cutting instruments. In addition, cost-effectiveness and frequent replacement cycles further reinforce the dominance of this segment. Hospitals also prefer standardized instrument sets for routine thoracic procedures, ensuring consistent adoption across healthcare facilities.

The robotic-assisted thoracic surgery systems segment is expected to witness the fastest growth rate of 22.8% from 2026 to 2033, fueled by increasing adoption of precision-driven surgical technologies in advanced hospitals. Robotic platforms enable superior dexterity, enhanced visualization, and minimally invasive tumor removal, significantly improving patient outcomes. Countries such as Japan, South Korea, and China are rapidly expanding robotic surgery infrastructure in tertiary care hospitals. Growing investments in AI-integrated surgical robotics and hybrid operating rooms are further accelerating adoption. In addition, increasing surgeon training programs and clinical evidence supporting robotic procedures are strengthening market penetration. The rising demand for high-precision, low-trauma surgical options is a key growth catalyst for this segment.

• By Surgical Procedure

On the basis of surgical procedure, the market is segmented into thoracotomy and minimally invasive surgery. The thoracotomy segment dominated the market with the largest revenue share of 55.1% in 2025, driven by its long-standing use as the standard open surgical approach for lung cancer resection. It remains widely practiced in hospitals with limited access to advanced minimally invasive infrastructure. Thoracotomy is often preferred in complex or late-stage cancer cases requiring extensive tumor removal. In many developing Asia-Pacific regions, the availability of trained surgeons and conventional surgical setups further supports its dominance. In addition, lower equipment dependency compared to advanced techniques contributes to its continued usage. Despite technological advancements, it remains a key procedure in high-volume public hospitals.

The minimally invasive surgery segment is expected to witness the fastest growth rate of 24.3% from 2026 to 2033, driven by increasing preference for less invasive and patient-friendly surgical approaches. Techniques such as video-assisted thoracic surgery (VATS) are widely adopted due to reduced hospital stays and faster recovery times. Growing awareness among patients and surgeons regarding postoperative benefits is accelerating demand. Advanced imaging systems and robotic integration are further improving procedural accuracy. Hospitals across China, India, and Southeast Asia are rapidly upgrading surgical capabilities to support minimally invasive techniques. The shift toward enhanced recovery protocols is a major factor driving this segment’s expansion.

• By Patient Type

On the basis of patient type, the market is segmented into male and female. The male segment dominated the market with the largest revenue share of 61.8% in 2025, primarily due to higher smoking prevalence, occupational exposure to carcinogens, and greater incidence of lung cancer among men across Asia-Pacific countries. Men account for a significantly larger proportion of diagnosed lung cancer cases, particularly in China and India. This higher disease burden directly translates into increased surgical intervention rates in male patients. In addition, late-stage diagnosis remains more common among male populations, requiring more extensive surgical management. Public health statistics consistently show a stronger clinical load in this demographic group.

The female segment is expected to witness the fastest growth rate of 18.9% from 2026 to 2033, driven by rising lung cancer incidence linked to environmental pollution, second-hand smoke exposure, and changing lifestyle factors. Increasing awareness and improved screening programs are leading to earlier diagnosis in women. Urbanization and rising exposure to indoor air pollution are also contributing to higher case detection rates. In addition, healthcare accessibility improvements are encouraging more female patients to undergo surgical treatment. Expanding gender-specific oncology awareness campaigns further support growth in this segment.

• By End User

On the basis of end user, the market is segmented into hospitals, ambulatory surgical centres, academic & research laboratories, speciality cancer care centres, and others. The hospitals segment dominated the market with the largest revenue share of 67.4% in 2025, driven by their strong infrastructure, availability of advanced surgical systems, and ability to handle complex lung cancer cases. Hospitals serve as primary centers for thoracic surgeries, especially in urban and tier-1 cities across Asia-Pacific. They are equipped with robotic-assisted systems, imaging technologies, and specialized surgical teams. High patient inflow and government funding further strengthen their dominance. In addition, multidisciplinary treatment capabilities make hospitals the preferred choice for lung cancer surgery.

The speciality cancer care centres segment is expected to witness the fastest growth rate of 21.5% from 2026 to 2033, driven by increasing demand for focused oncology services and advanced surgical expertise. These centres are rapidly expanding in countries such as China, India, and South Korea. They offer integrated cancer care including diagnosis, surgery, and post-operative rehabilitation. Rising investments from private healthcare providers are boosting infrastructure development. Patients increasingly prefer specialized centres for better clinical outcomes and advanced treatment protocols. The concentration of oncology specialists in these centres further accelerates their adoption.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, retail sales, online sales, and others. The direct tender segment dominated the market with the largest revenue share of 72.9% in 2025, driven by large-scale procurement of surgical instruments, robotic systems, and hospital equipment by government and institutional buyers. Public hospitals and healthcare networks primarily acquire advanced surgical systems through tenders. This channel ensures bulk purchasing, cost efficiency, and long-term service agreements. Strong government involvement in healthcare procurement across Asia-Pacific further strengthens dominance. In addition, major manufacturers prefer direct institutional contracts for high-value surgical systems.

The online sales segment is expected to witness the fastest growth rate of 19.7% from 2026 to 2033, driven by increasing digitization of medical procurement processes and growing adoption of e-commerce platforms for surgical consumables. Hospitals and clinics are increasingly purchasing smaller surgical instruments and accessories online. The convenience of price comparison and faster procurement is supporting growth. Rising penetration of digital healthcare supply chains in emerging economies is further accelerating adoption. In addition, small and mid-sized healthcare facilities prefer online platforms for cost-effective purchasing.

Asia-Pacific Lung Cancer Surgery Market Regional Analysis

• China dominated the Asia-Pacific lung cancer surgery market with the largest revenue share of 32.6% in 2025, characterized by a high patient pool, improving healthcare infrastructure, and strong government initiatives to expand oncology treatment access
• Healthcare providers in China are increasingly adopting minimally invasive and robotic-assisted thoracic surgery techniques, supported by continuous investments in hospital modernization and the expansion of specialized cancer treatment centers
• The country benefits from strong government initiatives focused on cancer screening, early diagnosis programs, and improved access to surgical oncology services, significantly boosting surgical intervention rates

The China Lung Cancer Surgery Market Insight

The China lung cancer surgery market captured the largest revenue share of 32.6% in 2025 within Asia-Pacific, fueled by the high prevalence of lung cancer, expanding oncology infrastructure, and strong government focus on cancer screening and early diagnosis programs. Hospitals are increasingly adopting advanced surgical techniques such as minimally invasive surgery and robotic-assisted thoracic procedures to improve clinical outcomes. The growing availability of specialized cancer centers and tertiary hospitals is further supporting surgical volumes. Moreover, continuous investments in modern surgical equipment, including endosurgical systems and advanced visualization technologies, are significantly contributing to market expansion.

Japan Lung Cancer Surgery Market Insight

The Japan lung cancer surgery market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by its advanced healthcare system, high adoption of robotic-assisted surgery, and strong emphasis on precision medicine. The country’s aging population is increasing lung cancer incidence, thereby boosting demand for surgical interventions. Japanese hospitals are widely integrating minimally invasive thoracic procedures supported by high-end imaging and monitoring systems. In addition, the presence of technologically advanced operating rooms and skilled thoracic surgeons is fostering improved surgical outcomes.

India Lung Cancer Surgery Market Insight

The India lung cancer surgery market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by rising lung cancer cases, expanding healthcare infrastructure, and increasing awareness regarding early diagnosis. The growing penetration of private hospitals and specialty cancer care centers is improving access to surgical treatments. India is also witnessing higher adoption of minimally invasive procedures due to cost-effectiveness and shorter recovery times. Furthermore, government initiatives promoting cancer care access and rising medical tourism are supporting market growth.

South Korea Lung Cancer Surgery Market Insight

The South Korea lung cancer surgery market is expected to expand at a considerable CAGR during the forecast period, fueled by strong technological adoption, high healthcare expenditure, and advanced hospital infrastructure. The country is a key adopter of robotic-assisted thoracic surgery systems, particularly in leading tertiary hospitals. Increasing prevalence of lung cancer and strong national screening programs are improving early detection rates. Moreover, integration of AI-based surgical planning tools and precision imaging systems is enhancing procedural accuracy and driving market expansion.

Asia-Pacific Lung Cancer Surgery Market Share

The Asia-Pacific Lung Cancer Surgery industry is primarily led by well-established companies, including:

• Medtronic (Ireland)
• Intuitive Surgical, Inc. (U.S.)
• Olympus Corporation (Japan)
• FUJIFILM Corporation (Japan)
• Ambu A/S (Denmark)
• Teleflex Incorporated (U.S.)
• Accuray Incorporated (U.S.)
• KARL STORZ SE & Co. KG (Germany)
• Richard Wolf GmbH (Germany)
• KLS Martin Group (Germany)
• Ackermann Instrumente GmbH (Germany)
• TROKAMED GmbH (Germany)
• asap endoscopic products GmbH (Germany)
• Surgical Holdings (U.K.)
• AngioDynamics, Inc. (U.S.)
• Scanlan International, Inc. (U.S.)
• Sontec Instruments, Inc. (U.S.)
• FusionKraft (Germany)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)

What are the Recent Developments in Asia-Pacific Lung Cancer Surgery Market?

• In January 2026, FV Hospital in Vietnam successfully performed a complex lung lobectomy using the Da Vinci Xi robotic surgical system, marking a major advancement in minimally invasive lung cancer surgery capabilities in Southeast Asia. The procedure demonstrated the ability of robotic surgery to remove lung tumors with high precision while minimizing patient trauma and recovery time. This development highlights the expanding adoption of robotic-assisted thoracic surgery across Asia-Pacific hospitals
• In March 2025, Chang Gung Memorial Hospital in Taiwan expanded its minimally invasive thoracic surgery capabilities through advanced robotic surgery programs, strengthening its position as a leading robotic surgery training hub in Asia-Pacific. The hospital has performed thousands of robotic surgeries and continues to train international surgeons in lung cancer surgical techniques
• In November 2024, Cedars-Sinai thoracic surgeons highlighted major advancements in robotic lung cancer surgery techniques, including improved precision, reduced invasiveness, and enhanced patient recovery outcomes. These innovations are influencing surgical practices globally, including Asia-Pacific hospitals adopting similar robotic and minimally invasive techniques. The development underscores the rapid evolution of thoracic oncology surgery standards
• In April 2024, research studies introduced AI-assisted and augmented reality (AR) technologies in robotic lung cancer surgery planning and execution, enabling surgeons to improve tumor localization and surgical precision during thoracic procedures. These innovations are being increasingly explored in Asia-Pacific healthcare systems to enhance minimally invasive surgical outcomes. The integration of AI with robotic surgery is reshaping lung cancer treatment approaches
• In May 2021, Olympus launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope, designed for minimally invasive lung cancer diagnosis and staging. This innovation strengthened early detection and surgical planning capabilities by improving biopsy accuracy and enabling better assessment of tumor spread before surgery

SKU-69313